PMID- 19252299
OWN - NLM
STAT- MEDLINE
DCOM- 20090428
LR  - 20190720
IS  - 0918-6158 (Print)
IS  - 0918-6158 (Linking)
VI  - 32
IP  - 3
DP  - 2009 Mar
TI  - Rescue of major histocompatibility-DR surface expression in 
      retinoblastoma-defective, non-small cell lung carcinoma cells by the MS-275 
      histone deacetylase inhibitor.
PG  - 480-2
AB  - Major histocompatibility (MHC) class II expression is ordinarily inducible by 
      interferon-gamma (IFN-gamma), but the induction is repressed in retinoblastoma 
      protein (Rb)-defective cells. The repression can be rescued by histone 
      deacetylase (HDAC) inhibitor treatment, but this has never been shown for an HDAC 
      inhibitor that is suitable for clinical trials and eventual patient therapy. Here 
      we demonstrate that the HDAC inhibitor, MS-275, can rescue the IFN-gamma 
      inducibility of human leukocyte antigen (HLA)-DR in non-small cell lung cancer 
      cells. This HDAC inhibitor is currently being tested in phase I/II clinical 
      trials for non-small cell lung cancer. We further verified that the MS-275 effect 
      is related to an HDAC tethered to the HLA-DRA promoter by the transcription 
      factor, YY1. HDAC inhibitors that can be used to treat patients may augment the 
      expression of tumor cell MHC class II, and the results suggest an opportunity to 
      determine the immunological consequences of HDAC inhibitor treatment in tumor 
      therapy.
FAU - Niesen, Melissa Ihla
AU  - Niesen MI
AD  - Department of Molecular Medicine, College of Medicine, University of South 
      Florida, Florida 33612, USA.
FAU - Blanck, George
AU  - Blanck G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Japan
TA  - Biol Pharm Bull
JT  - Biological & pharmaceutical bulletin
JID - 9311984
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Benzamides)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Histone Deacetylase Inhibitors)
RN  - 0 (Pyridines)
RN  - 0 (Retinoblastoma Protein)
RN  - 1ZNY4FKK9H (entinostat)
SB  - IM
MH  - Antineoplastic Agents/*pharmacology
MH  - Benzamides/*pharmacology
MH  - Carcinoma, Non-Small-Cell Lung
MH  - Cell Line, Tumor
MH  - HLA-DR Antigens/*biosynthesis
MH  - *Histone Deacetylase Inhibitors
MH  - Humans
MH  - Lung Neoplasms
MH  - Pyridines/*pharmacology
MH  - Retinoblastoma Protein/*metabolism
EDAT- 2009/03/03 09:00
MHDA- 2009/04/29 09:00
CRDT- 2009/03/03 09:00
PHST- 2009/03/03 09:00 [entrez]
PHST- 2009/03/03 09:00 [pubmed]
PHST- 2009/04/29 09:00 [medline]
AID - JST.JSTAGE/bpb/32.480 [pii]
AID - 10.1248/bpb.32.480 [doi]
PST - ppublish
SO  - Biol Pharm Bull. 2009 Mar;32(3):480-2. doi: 10.1248/bpb.32.480.